Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_3
1
20%
Ph not_applicable
1
20%
Ph phase_1
2
40%
Ph phase_2
1
20%

Phase Distribution

2

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
N/A1 (20.0%)

Trials by Status

completed240%
terminated240%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
terminatednot_applicable

Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator

NCT02413047
completedphase_2

Treatment of Older Adults With Acute Lymphoblastic Leukemia

NCT00973752
terminatedphase_1

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

NCT01094613
unknownphase_3

Adalimumab for the Management of Post-operative Crohn's Disease (CD)

NCT01629628
completedphase_1

Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients

NCT00774982

Clinical Trials (5)

Showing 5 of 5 trials
NCT02413047Not Applicable

Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator

Terminated
NCT00973752Phase 2

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Completed
NCT01094613Phase 1

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Terminated
NCT01629628Phase 3

Adalimumab for the Management of Post-operative Crohn's Disease (CD)

Unknown
NCT00774982Phase 1

Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5